JP2023538984A - 組織低酸素症及び敗血症の治療に使用するためのｌ－トリヨードチロニン（ｔ３）を含む医薬組成物 - Google Patents

組織低酸素症及び敗血症の治療に使用するためのｌ－トリヨードチロニン（ｔ３）を含む医薬組成物 Download PDF

Info

Publication number
JP2023538984A
JP2023538984A JP2022563957A JP2022563957A JP2023538984A JP 2023538984 A JP2023538984 A JP 2023538984A JP 2022563957 A JP2022563957 A JP 2022563957A JP 2022563957 A JP2022563957 A JP 2022563957A JP 2023538984 A JP2023538984 A JP 2023538984A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sepsis
hours
triiodothyronine
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563957A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538984A5 (https=
Inventor
コンスタンチノス，パントス
ヨルダニス，ムロウジス
Original Assignee
ユニファーマ クレオン ツェティス ファーマスーティカル ラボラトリーズ エス エー
ツェティ，ユリア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20200100200A external-priority patent/GR1010068B/el
Priority claimed from GR20200100695A external-priority patent/GR1010182B/el
Priority claimed from GR20210100216A external-priority patent/GR1010261B/el
Application filed by ユニファーマ クレオン ツェティス ファーマスーティカル ラボラトリーズ エス エー, ツェティ，ユリア filed Critical ユニファーマ クレオン ツェティス ファーマスーティカル ラボラトリーズ エス エー
Publication of JP2023538984A publication Critical patent/JP2023538984A/ja
Publication of JP2023538984A5 publication Critical patent/JP2023538984A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022563957A 2020-04-21 2021-04-15 組織低酸素症及び敗血症の治療に使用するためのｌ－トリヨードチロニン（ｔ３）を含む医薬組成物 Pending JP2023538984A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GR20200100200 2020-04-21
GR20200100200A GR1010068B (el) 2020-04-21 2020-04-21 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στη θεραπεια ασθενων σε κρισιμη κατασταση με λοιμωξη απο κορωνοϊο
GR20200100695 2020-11-23
GR20200100695A GR1010182B (el) 2020-11-23 2020-11-23 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
GR20210100216 2021-03-29
GR20210100216A GR1010261B (el) 2021-03-29 2021-03-29 Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
PCT/GR2021/000019 WO2021214497A1 (en) 2020-04-21 2021-04-15 Pharmaceutical composition comprising l-triiodothyronine (t3) for use in the treatment of tissue hypoxemia and sepsis

Publications (2)

Publication Number Publication Date
JP2023538984A true JP2023538984A (ja) 2023-09-13
JP2023538984A5 JP2023538984A5 (https=) 2024-04-23

Family

ID=76197481

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563957A Pending JP2023538984A (ja) 2020-04-21 2021-04-15 組織低酸素症及び敗血症の治療に使用するためのｌ－トリヨードチロニン（ｔ３）を含む医薬組成物

Country Status (13)

Country Link
US (1) US20230157982A1 (https=)
EP (1) EP4138810A1 (https=)
JP (1) JP2023538984A (https=)
KR (1) KR20230022839A (https=)
CN (1) CN115996710B (https=)
AU (1) AU2021258544A1 (https=)
BR (1) BR112022021250A2 (https=)
CA (1) CA3176106A1 (https=)
GE (2) GEP20247706B (https=)
IL (1) IL297398B1 (https=)
MX (1) MX2022013228A (https=)
WO (1) WO2021214497A1 (https=)
ZA (1) ZA202212502B (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3908272T1 (sl) 2019-01-09 2023-07-31 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. L-trijodotironin (t3) za uporabo pri omejevanju mikrovaskularne obstrukcije

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024919A1 (en) * 1994-03-15 1995-09-21 K.U. Leuven Research & Development New use of growth hormone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AYAKO MAKINO, ET AL.: ""Thyroid Hormone Receptor-β Is Associated with Coronary Angiogenesis during Pathological Cardiac Hy", ENDOCRINOLOGY, vol. 150, no. 4, JPN6025034901, 2009, pages 2008 - 2015, ISSN: 0005801995 *
JOURNAL OF CARDIOLOGY CASES, vol. 13, JPN6025011803, 2016, pages 33 - 36, ISSN: 0005801993 *
SEPSIS, vol. 2, JPN6025011804, 1998, pages 163 - 169, ISSN: 0005801994 *

Also Published As

Publication number Publication date
IL297398A (en) 2022-12-01
WO2021214497A1 (en) 2021-10-28
ZA202212502B (en) 2024-05-30
MX2022013228A (es) 2022-11-14
GEP20247706B (en) 2024-12-10
CA3176106A1 (en) 2021-10-28
AU2021258544A1 (en) 2022-10-27
IL297398B1 (en) 2026-01-01
BR112022021250A2 (pt) 2022-12-06
EP4138810A1 (en) 2023-03-01
GEAP202416094A (en) 2024-07-10
CN115996710A (zh) 2023-04-21
CN115996710B (zh) 2024-06-28
KR20230022839A (ko) 2023-02-16
US20230157982A1 (en) 2023-05-25

Similar Documents

Publication Publication Date Title
Joannidis et al. Prevention of acute kidney injury and protection of renal function in the intensive care unit: expert opinion of the working group for nephrology, ESICM
Brochard et al. An official ATS/ERS/ESICM/SCCM/SRLF statement: prevention and management of acute renal failure in the ICU patient: an international consensus conference in intensive care medicine
JP2021130710A (ja) ストレスタンパク質誘導剤を使用して獲得細胞抵抗性を誘導するための組成物、キット及び方法
US20080003301A1 (en) Copper lowering treatment of inflammatory and fibrotic diseases
US11213514B2 (en) Alpha-1-adrenergic receptor agonist therapy
AU2022209384A1 (en) Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
JP2025041648A (ja) 心血管有害事象のリスクのある対象における鉄欠乏症の処置
Monogiou Belik et al. The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice
CN115996710B (zh) 用于治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸（t3）的药物组合物
US20070248689A1 (en) Copper lowering treatment of inflammatory and fibrotic diseases
EP3403652A1 (en) Prevention and treatment of fibroblast growth factor 23 (fgf23)-associated disorders including chronic kidney disease (ckd)
AU2020206021B2 (en) Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
HK40088108A (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
HK40088108B (zh) 用於治疗组织缺氧和脓毒症的包含l-三碘甲腺原氨酸(t3)的药物组合物
EA048898B1 (ru) Фармацевтическая композиция, содержащая l-трийодтиронин (т3), для применения при лечении тканевой гипоксии и сепсиса
Ishihara Kidney function after the intraoperative use of 6% tetrastarches (HES 130/0.4 and 0.42)
WO2007129618A1 (ja) 好中球の活性化および遊走因子の抑制剤およびその利用
GR1010261B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της φλεγμονωδους αντιδρασης και της δυσλειτουργιας του καρδιαγγειακου συστηματος λογω σηψης
US20070032557A1 (en) Method for administering levosimendan
GR1010182B (el) Φαρμακευτικη συνθεση που περιεχει l-τριιωδοθυρονινη (τ3) για χρηση στην αντιμετωπιση της ιστικης υποξιας
Elfeil Anesthetic management of glycogen storage disease type 1b during liver transplantation: a case report
Mohamed Elsadek et al. Role of Magnesium Sulphate in Kidney and Coronary Artery Disease
Lucas et al. Sex determines cardiac and renal Vulnerability to chronic hemoglobin toxicity
EA046425B1 (ru) Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий
AU2007201085A1 (en) Copper lowering treatment of inflammatory and fibrotic diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221219

A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20221219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224